Profil
James E.
Berg has served as Vice President, Clinical and Regulatory Affairs, since March 1997.
Mr. Berg led the team responsible for the clinical trials program for docosanol 10% cream and had the responsibility for working with the FDA and other regulatory agencies that led to the approvals of the product in the U.S., Canada and Sweden and other countries.
Mr. Berg is also responsible for managing the clinical trials of Neurodex for the treatment of PBA and neuropathic pain and for the Company's lead compound for the treatment of allergy and asthma.
From August 1992 to March 1997, Mr. Berg was Director of Clinical Affairs and Product Development at the Company.
Earlier in his career, Mr. Berg held various sales and management positions at QUIDEL Corporation, San Diego, California, and at Krupp Bilstein Corporation of America, Inc., San Diego, California.
Mr. Berg received his B.A.
degree from the University of Wisconsin in 1973.
Anciens postes connus de James E. Berg
| Sociétés | Poste | Fin |
|---|---|---|
| AVANIR PHARMACEUTICALS INC | Conseiller Juridique Général | 07/11/2006 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Avanir Pharmaceuticals, Inc.
 Avanir Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Avanir Pharmaceuticals, Inc. engages in the development of therapeutic products for the treatment of nervous system disorder. The company was founded on August 31, 1988 and headquartered in Aliso Viejo, CA. | Health Technology |